Should paclitaxel be considered an old generation DCB? The limus era

Area of Science:

• Cardiovascular medicine
• Interventional cardiology
• Medical device technology

Background:

• Drug-Coated Balloons (DCBs) have evolved from treating in-stent restenosis to addressing small vessel disease and complex lesions.
• Paclitaxel has been the primary drug used in DCBs, but recent safety concerns have emerged.
• Sirolimus-eluting DCBs represent a new therapeutic option.

Purpose of the Study:

• To review the expanding applications of DCBs in interventional cardiology.
• To highlight the emergence of Sirolimus as an alternative to Paclitaxel in DCB technology.
• To discuss the evolving landscape of DCB therapy.

Main Methods:

• Review of current literature and clinical evidence on Drug-Coated Balloons.
• Analysis of safety and efficacy data for Paclitaxel- and Sirolimus-eluting DCBs.
• Discussion of clinical adoption trends in cath-lab practice.

Main Results:

• DCBs are now utilized for complex lesions, including bifurcations, large vessels, and acute coronary syndromes.
• Newer generation DCBs demonstrate improved performance and safety.
• Sirolimus-eluting DCBs are emerging as a viable alternative to Paclitaxel-eluting devices.

Conclusions:

• The clinical utility of DCBs is expanding beyond traditional indications.
• Sirolimus-eluting DCBs provide a valuable alternative to Paclitaxel, addressing recent safety concerns.
• The field of DCB technology continues to advance, offering new therapeutic possibilities.